August 20, 2024 10:49 AM EDTUpdated 03:34 PM
News Briefing

Kymera seeks to raise $225M; Ad­cen­do, Mul­ti­tude's new ADC deal

ENDPOINTS

Plus, news about Talus Bio­science, Mol­e­culin, Organon and Eli Lil­ly:

Kymera Ther­a­peu­tics aims to raise $225M: The pub­lic of­fer­ing will be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times